# Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure

> **NCT03059238** · PHASE3 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 213 (actual)

## Conditions studied

- Liver Cancer
- Pain Postoperative

## Interventions

- **DRUG:** Celecoxib 200mg oral capsule
- **DRUG:** parecoxib sodium
- **DRUG:** controlled-release oxycodone

## Key facts

- **NCT ID:** NCT03059238
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03059238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03059238, "Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03059238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*